Mechanism and effects of extramedullary hematopoiesis on anti-tumor immunity

References

1. 1.↵
   2. Medvinsky A,
   3. Rybtsov S,
   4. Taoudi S.

   Embryonic origin of the adult hematopoietic system: advances and questions. Development. 2011; 138: 1017–31.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   2. Mazo IB,
   3. Massberg S,
   4. von Andrian UH.

   Hematopoietic stem and progenitor cell trafficking. Trends Immunol. 2011; 32: 493–503.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Yang X,
   3. Chen D,
   4. Long H,
   5. Zhu B.

   The mechanisms of pathological extramedullary hematopoiesis in diseases. Cell Mol Life Sci. 2020; 77: 2723–38.

   OpenUrlCrossRef
4. 4.↵
   2. Dulmovits BM,
   3. Tang Y,
   4. Papoin J,
   5. He M,
   6. Li J,
   7. Yang H, et al.

   HMGB1-mediated restriction of epo signaling contributes to anemia of inflammation. Blood. 2022; 139: 3181–93.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Dicato M,
   3. Plawny L,
   4. Diederich M.

   Anemia in cancer. Ann Oncol. 2010; 21 Suppl 7: vii167–72.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Xu Z,
   3. Huang X.

   Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. Cancer Biol Med. 2021; 18: 966–80.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   2. Sohawon D,
   3. Lau KK,
   4. Lau T,
   5. Bowden DK.

   Extra-medullary haematopoiesis: a pictorial review of its typical and atypical locations. J Med Imaging Radiat Oncol. 2012; 56: 538–44.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Johns JL,
   3. Christopher MM.

   Extramedullary hematopoiesis: a new look at the underlying stem cell niche, theories of development, and occurrence in animals. Vet Pathol. 2012; 49: 508–23.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Fan N,
   3. Lavu S,
   4. Hanson CA,
   5. Tefferi A.

   Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo clinic case series of 309 patients. Blood Cancer J. 2018; 8: 119.

   OpenUrl
10. 10.↵
    2. Rashidi A,
    3. Courville E.

    Massive splenomegaly. N Engl J Med. 2019; 381: e11.
11. 11.↵
    2. Wu C,
    3. Ning H,
    4. Liu M,
    5. Lin J,
    6. Luo S,
    7. Zhu W, et al.

    Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018; 128: 3425–38.

    OpenUrlCrossRefPubMed
12. 12.↵
    2. Liu M,
    3. Wu C,
    4. Luo S,
    5. Hua Q,
    6. Chen HT,
    7. Weng Y, et al.

    Perk reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. J Exp Med. 2022; 219: e20211498.
13. 13.↵
    2. Zhao L,
    3. He R,
    4. Long H,
    5. Guo B,
    6. Jia Q,
    7. Qin D, et al.

    Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells. Nat Med. 2018; 24: 1536–44.

    OpenUrlCrossRef
14. 14.↵
    2. Harashima A,
    3. Suzuki M,
    4. Okochi A,
    5. Yamamoto M,
    6. Matsuo Y,
    7. Motoda R, et al.

    CD45 tyrosine phosphatase inhibits erythroid differentiation of umbilical cord blood CD34+ cells associated with selective inactivation of lyn. Blood. 2002; 100: 4440–5.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    2. Hou Y,
    3. Liang HL,
    4. Yu X,
    5. Liu Z,
    6. Cao X,
    7. Rao E, et al.

    Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021; 13: eabb0130.
16. 16.↵
    2. Han Y,
    3. Liu Q,
    4. Hou J,
    5. Gu Y,
    6. Zhang Y,
    7. Chen Z, et al.

    Tumor-induced generation of splenic erythroblast-like ter-cells promotes tumor progression. Cell. 2018; 173: 634–48.e12.

    OpenUrlCrossRef
17. 17.↵
    2. Long H,
    3. Jia Q,
    4. Wang L,
    5. Fang W,
    6. Wang Z,
    7. Jiang T, et al.

    Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-l1 treatment efficacy. Cancer Cell. 2022; 40: 674–93.e7.

    OpenUrlCrossRef
18. 18.↵
    2. Chen J,
    3. Qiao YD,
    4. Li X,
    5. Xu JL,
    6. Ye QJ,
    7. Jiang N, et al.

    Intratumoral CD45(+)CD71(+) erythroid cells induce immune tolerance and predict tumor recurrence in hepatocellular carcinoma. Cancer Lett. 2021; 499: 85–98.

    OpenUrl
19. 19.↵
    2. Steinberg D.

    Anemia and cancer. CA Cancer J Clin. 1989; 39: 296–304.

    OpenUrlCrossRefPubMed
20. 20.↵
    2. Oh DY,
    3. Lee KH,
    4. Lee DW,
    5. Yoon J,
    6. Kim TY,
    7. Bang JH, et al.

    Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022; 7: 522–32.

    OpenUrlCrossRef